Immuneering Corporation Other than Temporary Impairment Losses, Investments
Immuneering Corporation (IMRX) reported Other than Temporary Impairment Losses, Investments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2023-05-04
- Immuneering Corporation other than temporary impairment losses, investments for the quarter ending 2022-12-31 was $0.00.
- Immuneering Corporation other than temporary impairment losses, investments for the quarter ending 2022-09-30 was $0.00.
- Immuneering Corporation other than temporary impairment losses, investments for the quarter ending 2022-06-30 was $0.00.
- Immuneering Corporation other than temporary impairment losses, investments for the quarter ending 2022-03-31 was $0.00.
- Immuneering Corporation other than temporary impairment losses, investments for fiscal 2022 was $0.00.
- Immuneering Corporation other than temporary impairment losses, investments for fiscal 2021 was $0.00.
| Period end | Other than Temporary Impairment Losses, Investments 3 month | Other than Temporary Impairment Losses, Investments 6 month | Other than Temporary Impairment Losses, Investments 9 month | Other than Temporary Impairment Losses, Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-04 | $0.00 derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | $0.00 derived: sum of 3 quarters · filed 2023-05-04 | $0.00 derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |